U01DA059791

PF614-MPAR: Clinical development of opioid with oral overdose protection - Abstract

Prescription opioid abuse, addiction and overdose are major burdens to patients and society, resulting in significant costs, illnesses, and deaths.

The intertwined issues of I) the ongoing abuse of prescription opioids, and II) reluctance of prescribers to write prescriptions for opioid analgesics, have resulted in the under-treatment of patients with moderate-to-severe pain.

Several abuse-deterrent opioid products (primarily formulations) are currently marketed, but they fall short of being resistant to abuse.

Notably, currently marketed abuse deterrent technologies do not effectively deter one of the most common forms of opioid abuse – swallowing an increased number of tablets or capsules than are prescribed.

In order to address this crisis, Ensysce Biosciences has created two complementary, novel technologies that control the release of known opioids.

The abuse resistant and overdose protection features of Ensysce Biosciences’ TAAP™ (Trypsin Activated Abuse Protection) with MPAR® (Multi-Pill-Abuse-Resistant) prodrugs are built into the chemical modification of the opioid and are not just formulation-based changes.

PF614-MPAR is the first opioid being developed with overdose protection.

PF614-MPAR is a combination product of the TAAP-Oxycodone prodrug, PF614, and the trypsin inhibitor Nafamostat.

Because exposure to trypsin is required to activate PF614 for the release of oxycodone, it provides a number of features that deter abuse while addition of Nafamostat adds the overdose protection.

As a combination product, we have filed two INDs to evaluate both PF614 and the trypsin inhibitor separately for safety and PK, and have filed a third IND to evaluate the combination.

The data from the Phase 1 study that evaluated the combination of PF614 and Nafamostat have provided the first proof of concept that we can deliver pain relieving levels of oxycodone from PF614-MPAR administration and still achieve overdose protection.

The overdose protection of PF614-MPAR only is activated when more than a prescribed dose is taken at one time.

The amount of Nafamostat in a dose unit of PF614-MPAR is designed to be ineffective when taken at the prescribed dose.

However, small increments over the prescribed dose or if taken in large excess, the increased amount of Nafamostat will inhibit the trypsin conversion of PF614 to oxycodone reducing the opioid release.

It is designed to put the brakes on the activation of PF614 if too much is taken at one time, averting an overdose.

We have now examined the PF614-MPAR 25 mg dosage strength in a two-part Phase 1 study and found that the combination showed an equivalent safety profile to PF614 alone.

A 25 mg PF614-MPAR dose unit was defined in part 1 of the study and proof-of-concept was demonstrated successfully when overdose protection was provided when excess PF614-MPAR 25 mg was taken simultaneously in part 2.

PF614-MPAR was designed to allow an anticipated prescribed dose of 1 to 2 dose units twice daily to provide relief from severe pain.

If more than a prescribed dose is consumed, the increased amount of Nafamostat ingested from the combination product is sufficient to inhibit the activity of trypsin, therefore allowing excess inactive PF614 prodrug to pass through the body unchanged and ultimately prevent an overdose.

The objective of this proposal is to continue the clinical development of PF614-MPAR to ensure all dosage strengths 25, 50 and 100 mg have the same ability to provide pain relief at prescribed dose but overdose protection at greater than prescribed dose levels.

A multi-ascending dose study will evaluate PF614-MPAR 25, 50 and 100 mg for safety and ensure that repeat dosing of the combination product does not result in attenuation of the oxycodone release from PF614 at anticipated prescribed doses of 2 pill equivalents delivered orally, twice daily.

These studies will be carried out in parallel with non-clinical studies that are needed to support a new drug application.

Ensysce Biosciences

TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.279 - Drug Abuse and Addiction Research Programs

National Institute on Drug Abuse (NIDA) [HHS - NIH]

La Jolla, California 920374517 United States

Single Zip Code

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) (PAR-22-202)

Amendment Since initial award the total obligations have increased 116% from $4,572,695 to $9,861,616.